Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Niccolò Bolli

Showing results (71-80 of 84) with videos related to

Pageof 9
Sort By:
Blood|May 25, 2006
Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemiaBrunangelo Falini, Maria Paola Martelli, Niccolò Bolli, et al.
Blood|January 10, 2023
Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signaturesBenjamin Diamond, Bachisio Ziccheddu, Kylee Maclachlan, et al.
Blood|June 2, 2021
Specific targeting of the KRAS mutational landscape in myeloma as a tool to unveil the elicited antitumor activityAntonio Sacco, Cinzia Federico, Katia Todoerti, et al.
Hemasphere|October 15, 2025
European Myeloma Network Group Consensus Statement on the use of next-generation sequencing for prognostic stratification of newly diagnosed multiple myelomaNiccolò Bolli, Mattia D'Agostino, Tina Bagratuni, et al.
Ebiomedicine|December 19, 2023
Circulating biomarkers in familial cerebral cavernous malformationFrancesca Lazzaroni, Jennifer M T A Meessen, Ying Sun, et al.
Cancer Medicine|March 17, 2026
Next Generation Flow and Next Generation Sequencing for Measurable Residual Disease Assessment in Multiple Myeloma Patients: A Real-Life Italian Multicenter Harmonization ExperienceStefania Oliva, Marina Martello, Elona Saraci, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2024
Genomic Classification and Individualized Prognosis in Multiple MyelomaFrancesco Maura, Arjun Raj Rajanna, Bachisio Ziccheddu, et al.
Hematological Oncology|February 3, 2025
Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab-Refractory Multiple Myeloma Patients: A Multicenter Real-World StudyEnrica Antonia Martino, Daniele Derudas, Elena Rossi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 4, 2021
Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic SyndromesMatteo Bersanelli, Erica Travaglino, Manja Meggendorfer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2025
International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple MyelomaHervé Avet-Loiseau, Faith E Davies, Mehmet K Samur, et al.
Pageof 9

Showing results (71-80 of 84) with videos related to

Sort By:
Pageof 9
Blood|May 25, 2006
Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemiaBrunangelo Falini, Maria Paola Martelli, Niccolò Bolli, et al.
Blood|January 10, 2023
Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signaturesBenjamin Diamond, Bachisio Ziccheddu, Kylee Maclachlan, et al.
Blood|June 2, 2021
Specific targeting of the KRAS mutational landscape in myeloma as a tool to unveil the elicited antitumor activityAntonio Sacco, Cinzia Federico, Katia Todoerti, et al.
Hemasphere|October 15, 2025
European Myeloma Network Group Consensus Statement on the use of next-generation sequencing for prognostic stratification of newly diagnosed multiple myelomaNiccolò Bolli, Mattia D'Agostino, Tina Bagratuni, et al.
Ebiomedicine|December 19, 2023
Circulating biomarkers in familial cerebral cavernous malformationFrancesca Lazzaroni, Jennifer M T A Meessen, Ying Sun, et al.
Cancer Medicine|March 17, 2026
Next Generation Flow and Next Generation Sequencing for Measurable Residual Disease Assessment in Multiple Myeloma Patients: A Real-Life Italian Multicenter Harmonization ExperienceStefania Oliva, Marina Martello, Elona Saraci, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2024
Genomic Classification and Individualized Prognosis in Multiple MyelomaFrancesco Maura, Arjun Raj Rajanna, Bachisio Ziccheddu, et al.
Hematological Oncology|February 3, 2025
Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab-Refractory Multiple Myeloma Patients: A Multicenter Real-World StudyEnrica Antonia Martino, Daniele Derudas, Elena Rossi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 4, 2021
Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic SyndromesMatteo Bersanelli, Erica Travaglino, Manja Meggendorfer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2025
International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple MyelomaHervé Avet-Loiseau, Faith E Davies, Mehmet K Samur, et al.
Pageof 9